Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
| Revenue (TTM) | $2.68B |
| Gross Profit (TTM) | $1.93B |
| EBITDA | $591.01M |
| Operating Margin | 20.00% |
| Return on Equity | 77.20% |
| Return on Assets | 17.50% |
| Revenue/Share (TTM) | $94.44 |
| Book Value | $20.95 |
| Price-to-Book | 26.62 |
| Price-to-Sales (TTM) | 5.58 |
| EV/Revenue | 5.75 |
| EV/EBITDA | 26.05 |
| Quarterly Earnings Growth (YoY) | 16.60% |
| Quarterly Revenue Growth (YoY) | 26.50% |
| Shares Outstanding | $28.56M |
| Float | $23.00M |
| % Insiders | 19.43% |
| % Institutions | 88.50% |
Volatility is currently expanding
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.
In the closing of the recent trading day, Medpace (MEDP) stood at $543.57, denoting a +2.64% move from the preceding trading day.
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Medpace (MEDP) reached $519.96 at the closing of the latest trading day, reflecting a +1.4% change compared to its last close.
Medpace (MEDP) closed the most recent trading day at $461.6, moving 1.26% from the previous trading session.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2026 financial results after the market close on Wednesday, July 22, 2026. The Company will host a conference call the following morning, Thursday, July 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you joi.
Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
NEW YORK--(BUSINESS WIRE)---- $MEDP #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) and reminds investors of the June 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The fir.
New York, New York--(Newsfile Corp. - June 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the "Class Period"), of the important June 8, 2026 lead plaintiff deadline. SO WHAT: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
